Hims & Hers Health, Inc.

Neutral/Bullish

Last updated: 6/17/2025

Executive Summary

Hims & Hers Health, Inc., a telehealth company founded in 2017, has rapidly established itself as a leader in the digital health space by providing accessible healthcare solutions through a direct-to-consumer model. The company has reported impressive revenue growth, achieving $1.48 billion in FY2024, alongside a positive EBITDA of $0.08 billion, reflecting strong operational performance. Recent strategic moves, including the acquisition of UK-based telehealth startup Zava and plans to introduce obesity treatments in Europe, signal Hims & Hers' commitment to expanding its market presence and diversifying its product offerings.

However, Hims & Hers faces significant risks, including high valuation metrics that may suggest overvaluation, increased competition from traditional healthcare providers, and potential regulatory changes that could impact operations. Additionally, the integration of Zava presents its own challenges, and limited financial disclosures complicate the assessment of the company's overall health. As Hims & Hers navigates these complexities, its ability to innovate and adapt will be crucial for sustaining growth and maintaining investor confidence in a competitive landscape.

The Hims & Hers Health, Inc. Story

Founded in 2017 and headquartered in San Francisco, California, Hims & Hers Health, Inc. is a telehealth company that focuses on providing accessible healthcare solutions for a range of personal health issues, including sexual health, hair loss, and skincare. The company operates on a direct-to-consumer model, leveraging technology to connect patients with licensed medical professionals who can prescribe treatments online.

Since its inception, Hims & Hers has achieved significant milestones, including a successful IPO in early 2021, which underscored its rapid growth and popularity among consumers seeking discreet and convenient healthcare options. The company has expanded its product offerings beyond its initial focus on men's health to include services tailored for women, reflecting a strategic pivot to address a broader market. This expansion has allowed Hims & Hers to establish itself as a leader in the digital health space, continuously innovating to meet the evolving needs of its customers.

Macro Industry Position

The telehealth industry, where Hims & Hers Health, Inc. operates, has experienced significant growth, driven by the COVID-19 pandemic and a shift towards digital health solutions. According to a report by McKinsey & Company, telehealth utilization stabilized at 38 times higher than pre-pandemic levels as of mid-2021, indicating a lasting change in consumer behavior towards remote healthcare services. However, the industry faces challenges from regulatory changes and increased competition, particularly as traditional healthcare providers expand their digital offerings.

Hims & Hers Health, Inc. has positioned itself as a leader in the direct-to-consumer telehealth space, focusing on wellness and personal care products. As of Q2 2023, the company reported a 30% year-over-year increase in revenue, reaching $100 million, which underscores its strong market presence among peers like Roman and Lemonaid Health. Yet, how does Hims & Hers differentiate itself in such a crowded market? The company leverages its brand identity and a diverse product portfolio that includes prescription medications, over-the-counter products, and wellness services, allowing it to cater to a broad audience.

Geopolitical factors, such as ongoing healthcare reforms and potential changes in telehealth regulations, continue to shape the landscape. The Biden administration's focus on expanding access to telehealth services has been a boon for companies like Hims & Hers, as it aligns with their mission to provide accessible healthcare solutions. As of now, Hims & Hers remains committed to expanding its offerings and enhancing user experience, ensuring it stays competitive in an evolving market.

Recent Developments

Hims & Hers Health, Inc. has announced its plans to acquire the UK-based telehealth startup Zava, marking a significant step in its strategy to expand its international presence. This acquisition is expected to enhance Hims & Hers' offerings across key European markets, including the UK, Germany, France, and Ireland. The financial details of the deal have not been disclosed, but the move is seen as a pivotal moment for the company as it seeks to broaden its reach in the growing telehealth sector.

In addition to the acquisition, Hims & Hers is also looking to introduce replica obesity drugs in the UK and Europe. This initiative aligns with the company's broader goal of diversifying its product offerings and tapping into the lucrative market for obesity treatments. By expanding its portfolio, Hims & Hers aims to position itself as a leader in the digital health space, catering to a growing demand for accessible healthcare solutions.

For investors, these developments suggest a proactive approach by Hims & Hers to strengthen its market position and drive growth in international markets. However, the success of these initiatives will depend on effective integration of Zava and the acceptance of new products in competitive environments. As the company navigates this expansion, investors should monitor its performance closely to assess the potential impact on stock value and overall business sustainability.

Financial Deep-Dive

Financial Health Summary

Hims & Hers Health, Inc. reported a remarkable revenue growth in FY2024, achieving $1.48 billion compared to $0.87 billion in FY2023. This growth trajectory is further supported by a positive EBITDA of $0.08 billion, a significant turnaround from the previous year's loss of $0.02 billion. In the latest quarter, the company maintained this momentum with revenue of $0.59 billion, an EBITDA of $0.07 billion, and operating cash flow of $0.25 billion, indicating a robust operational performance.

While Hims & Hers Health, Inc. showcases impressive revenue growth, several key metrics warrant attention. The company's market capitalization stands at $12.88 billion, with a price-to-earnings ratio of 80.72, suggesting that investors may be pricing in high growth expectations. However, the enterprise-value-to-EBITDA multiple of 95.79 and the EV-to-free-cash-flow ratio of 52.74 indicate potential overvaluation concerns. Additionally, the cash per share is $1.45, which, while positive, raises questions about liquidity given the company's cash-flow challenges reflected in the decrease of operating cash flow per share.

The single biggest financial risk for investors in Hims & Hers Health, Inc. is the company's high valuation metrics, particularly the price-to-sales ratio of 7.22 and the PEG ratio of 2.75, which may not be sustainable if growth slows. Furthermore, the limited disclosure of financial metrics could hinder a comprehensive analysis of the company's financial health. Investors should closely monitor these valuation metrics and the company's ability to maintain its growth trajectory in a competitive landscape.

Verdict: Hims & Hers Health, Inc. demonstrates strong revenue growth and a positive EBITDA, but its high valuation ratios and limited financial disclosures present significant risks that investors must consider.

Risks and Concerns

Hims & Hers Health, Inc. operates in a highly competitive telehealth market, which presents significant risks to its growth trajectory. The company's market capitalization of $12.88 billion and a price-to-earnings ratio of 80.72 suggest that investors have high expectations for future growth. However, these elevated valuation metrics, including a price-to-sales ratio of 7.22 and a PEG ratio of 2.75, raise concerns about potential overvaluation, particularly if the company fails to sustain its impressive revenue growth of 30% year-over-year as reported in Q2 2023.

Moreover, the telehealth industry is subject to evolving regulatory landscapes that could impact operational effectiveness. As the Biden administration focuses on expanding access to telehealth services, any changes in regulations could create uncertainty for Hims & Hers. Additionally, the integration of the UK-based telehealth startup Zava poses its own set of risks, as successful execution will be crucial for enhancing the company's offerings in competitive European markets. Investors must remain vigilant about how these factors could affect the company's performance and market position.

Lastly, the limited disclosure of financial metrics complicates a comprehensive analysis of Hims & Hers' financial health. While the company reported a positive EBITDA of $0.08 billion in FY2024, the decrease in operating cash flow per share raises liquidity concerns. As the company seeks to diversify its product offerings and expand internationally, it must navigate these financial challenges carefully to maintain investor confidence and ensure long-term sustainability in a rapidly changing healthcare landscape.

Outlook

As Hims & Hers Health, Inc. navigates the evolving landscape of telehealth and wellness, its future prospects appear to hinge on a blend of innovation, market positioning, and consumer engagement. The company’s commitment to expanding its product offerings and enhancing user experience could serve as a catalyst for growth, particularly as more individuals seek accessible and personalized healthcare solutions. However, the competitive nature of the telehealth sector and potential regulatory challenges may pose hurdles that require strategic agility and adaptability.

Looking ahead, Hims & Hers has the opportunity to solidify its brand as a trusted provider of health and wellness solutions, especially among younger demographics increasingly prioritizing mental and physical well-being. The integration of technology in healthcare delivery presents a unique avenue for the company to differentiate itself, potentially leading to increased customer loyalty and market share. Nevertheless, the company must remain vigilant in addressing consumer concerns regarding privacy and data security, as these factors will be crucial in maintaining trust and fostering long-term relationships with its user base. Overall, Hims & Hers stands at a pivotal juncture, where its ability to innovate and respond to market dynamics will significantly influence its trajectory in the coming years.

Red & Green Flags

This section distills all of the report’s positives (green flags), negatives (red flags) and open questions (unknowns) into one place.

Action Checklist

Below are the next research steps a retail investor should consider based on this report.

Disclaimer

This Company Report is based on publicly available information and original research, and is provided for informational purposes only. It does not constitute financial, investment, or legal advice, nor an offer or solicitation to buy or sell any security. Readers should conduct their own due diligence and consult qualified advisors before making any investment decisions. Company performance can change rapidly and past results are not a guarantee of future outcomes. The author and publisher accept no responsibility for any actions taken based on this report.